Trevi Therapeutics (TRVI) News Today $4.75 -0.05 (-0.98%) As of 12:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus rating of "Buy" by the ten research firms that are currently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating toFebruary 21 at 4:04 AM | marketbeat.comTrevi Therapeutics price target raised to $12 from $8 at StifelFebruary 20 at 6:44 PM | markets.businessinsider.comWhy Trevi Therapeutics (TRVI) Is Advancing TodayFebruary 20 at 6:44 PM | msn.comFY2029 Earnings Estimate for TRVI Issued By B. RileyTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at B. Riley issued their FY2029 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Thursday, February 13th. B. Riley analyst M. Mamtani forecasts that the company will earn ($0.95) per shFebruary 17, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest UpdateTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 3,870,000 shares, a drop of 17.0% from the December 31st total of 4,660,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is currently 2.3 days.January 31, 2025 | marketbeat.comJPMorgan Chase & Co. Has $336,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)JPMorgan Chase & Co. increased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 220.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,517 shares of the company's stock after buyiJanuary 31, 2025 | marketbeat.comTrevi Therapeutics to Participate in Upcoming February Investor ConferencesJanuary 30, 2025 | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by BrokeragesTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned a consensus recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation onJanuary 27, 2025 | marketbeat.comFY2024 Earnings Forecast for TRVI Issued By Leerink PartnrsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Trevi Therapeutics in a report issued on Tuesday, January 21st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per shaJanuary 23, 2025 | marketbeat.comPromising Potential of Trevi Therapeutics’ Haduvio in IPF Cough Drives Buy Rating Amid RCC ChallengesJanuary 22, 2025 | markets.businessinsider.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Decline in Short InterestTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 3,870,000 shares, a drop of 17.0% from the December 15th total of 4,660,000 shares. Based on an average trading volume of 1,690,000 shares, the short-interest ratio is presently 2.3 days.January 16, 2025 | marketbeat.comOptimistic Outlook on Trevi Therapeutics Amid Promising Developments and Strategic ProgressJanuary 13, 2025 | markets.businessinsider.comTrevi Therapeutics’ Promising Trial Timelines and Market Opportunities Drive Buy RatingJanuary 8, 2025 | markets.businessinsider.comTrevi Therapeutics’ Haduvio: Strong Buy Rating Backed by Promising Clinical Progress and Financial StabilityJanuary 8, 2025 | markets.businessinsider.comD. Boral Capital Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)D. Boral Capital reiterated a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday.January 8, 2025 | marketbeat.comTrevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | prnewswire.comGeode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Geode Capital Management LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 10.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,264,166 shares of the companJanuary 6, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average rating of "Buy" from the ten brokerages that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company.January 2, 2025 | marketbeat.comRome’s iconic Trevi Fountain reopens after renovation work in time for the Jubilee Holy YearDecember 24, 2024 | msn.comTrevi Therapeutics Announces Pricing of $50 Million Underwritten OfferingDecember 16, 2024 | prnewswire.comOptimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial ResultsDecember 13, 2024 | markets.businessinsider.comRetail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%December 13, 2024 | msn.comPositive Outlook on Trevi Therapeutics: Stable Phase 2b Trial Results Boost Confidence in Haduvio and Market PotentialDecember 12, 2024 | markets.businessinsider.comTrevi Therapeutics Shares Hit 52-Week High After Positive Trial AnalysisDecember 12, 2024 | marketwatch.comTrevi stock rockets on Haduvio study updateDecember 12, 2024 | seekingalpha.comTrevi Reports Positive Outcome From Sample Size Re-estimation For Phase 2b CORAL Study; Stock UpDecember 12, 2024 | markets.businessinsider.comTrevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic CoughDecember 12, 2024 | prnewswire.comHC Wainwright Predicts Lower Earnings for Trevi TherapeuticsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued on Wednesday, December 4th. HC Wainwright analyst O. Livnat now anticipates that the company will pDecember 9, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by BrokeragesShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buDecember 8, 2024 | marketbeat.comBuy Rating Affirmed for Trevi Therapeutics: Haduvio’s Market Potential Outweighs Scheduling ConcernsDecember 6, 2024 | markets.businessinsider.comBuy Rating for Trevi Therapeutics: Strong HAP Study Results and Potential Catalysts Bolster ConfidenceDecember 6, 2024 | markets.businessinsider.comJonesTrading Remains a Buy on Trevi Therapeutics (TRVI)December 5, 2024 | markets.businessinsider.comTrevi Therapeutics: Undervalued Stock with High Potential in Chronic Cough Market Despite Low Abuse ConcernsDecember 5, 2024 | markets.businessinsider.comOppenheimer Remains a Buy on Trevi Therapeutics (TRVI)December 5, 2024 | markets.businessinsider.comTrevi Therapeutics price target raised to $9 from $8 at JonesResearchDecember 5, 2024 | markets.businessinsider.comCompanies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In GrowthDecember 4, 2024 | finance.yahoo.comTrevi Therapeutics Reports Positive Results for Human-Abuse Potential of Oral NalbuphineDecember 3, 2024 | marketwatch.comTrevi stock tumbles 23% amid Haduvio study resultsDecember 3, 2024 | msn.comTrevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral NalbuphineDecember 3, 2024 | prnewswire.comTrevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 21, 2024 | prnewswire.comPromising Prospects for Trevi Therapeutics’ Haduvio in Addressing Unmet Needs in Refractory Chronic CoughNovember 18, 2024 | markets.businessinsider.comRome’s Trevi Fountain unveils elevated walkway for tourists to get closer look during cleaningNovember 14, 2024 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by AnalystsShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and two hNovember 13, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of TRVI FY2024 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Trevi Therapeutics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earNovember 11, 2024 | marketbeat.comRome's Trevi Fountain gets temporary catwalk as famous landmark undergoes a cleaningNovember 10, 2024 | msn.comTourists in Rome now have a walkway to visit the Trevi Fountain but can’t toss coinsNovember 10, 2024 | apnews.comTrevi Therapeutics: Buy Rating Driven by Promising Haduvio Potential and Key Study DevelopmentsNovember 9, 2024 | markets.businessinsider.comTrevi Therapeutics: Promising Pipeline and Strategic Developments Support Buy RatingNovember 9, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comTrevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Prospects and Upcoming Data MilestonesNovember 8, 2024 | markets.businessinsider.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼1.020.60▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼73▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANIP News DAWN News ADPT News RCUS News CALT News SYRE News SPRY News OCUL News XNCR News ETNB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts